ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTWhy I'm Holding onto Hope for Nano in OncologyChristine Allen*View Author Information Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street Toronto, Ontario, Canada, M5S 3M2*E-mail: [email protected]Cite this: Mol. Pharmaceutics 2016, 13, 8, 2603–2604Publication Date (Web):July 12, 2016Publication History Received17 June 2016Accepted12 July 2016Revised8 July 2016Published online15 July 2016Published inissue 1 August 2016https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.6b00547https://doi.org/10.1021/acs.molpharmaceut.6b00547review-articleACS PublicationsCopyright © 2016 American Chemical Society. This publication is licensed under these Terms of Use. Request reuse permissions This publication is Open Access under the license indicated. Learn MoreArticle Views1943Altmetric-Citations17LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstract
No takes yet. Share an insight, caveat, or question.
Christine Allen (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: